APUS Stock Apimeds Pharmaceuticals US (APUS, $2.02) was a top gainer for penny stocks yesterday, jumping +10.38% to $2.02 per share
at Tickeron.com
Loading...
APUS sees its Stochastic Oscillator climbs out of oversold territory
On October 08, 2025, the Stochastic Oscillator for APUS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 3 instances where the indicator left the oversold zone. In of the 3 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2025. You may want to consider a long position or call options on APUS as a result. In of 6 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APUS advanced for three days, in of 11 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for APUS turned negative on October 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 2 similar instances when the indicator turned negative. In of the 2 cases the stock turned lower in the days that followed. This puts the odds of success at .
APUS moved below its 50-day moving average on October 13, 2025 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for APUS entered a downward trend on October 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.325) is normal, around the industry mean (17.643). P/E Ratio (0.000) is within average values for comparable stocks, (72.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.089). APUS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (0.000) is also within normal values, averaging (48.567).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. APUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Advertisement